SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Vesikari Timo)
 

Search: WFRF:(Vesikari Timo) > (2015-2019) > Meningococcal Serog...

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.

Vesikari, Timo (author)
Østergaard, Lars (author)
Diez-Domingo, Javier (author)
show more...
Wysocki, Jacek (author)
Flodmark, Carl-Erik (author)
Lund University,Lunds universitet,Preventiv pediatrik,Forskargrupper vid Lunds universitet,Preventive Paediatrics,Lund University Research Groups
Beeslaar, Johannes (author)
Eiden, Joseph (author)
Jiang, Qin (author)
Jansen, Kathrin U (author)
Jones, Thomas R (author)
Harris, Shannon L (author)
O'Neill, Robert E (author)
York, Laura J (author)
Crowther, Graham (author)
Perez, John L (author)
show less...
 (creator_code:org_t)
2015-08-04
2016
English.
In: Journal of the Pediatric Infectious Diseases Society. - : Oxford University Press (OUP). - 2048-7207 .- 2048-7193.
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Neisseria meningitidis serogroup B (MnB) is a leading cause of invasive meningococcal disease in adolescents and young adults. A recombinant factor H binding protein (fHBP) vaccine (Trumenba(®); bivalent rLP2086) was recently approved in the United States in individuals aged 10-25 years. Immunogenicity and safety of 2- or 3-dose schedules of bivalent rLP2086 were assessed in adolescents.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view